Comorbidities in Patients with Gout

Erdal Bodakçi

Article Details

Comorbidities in Patients with Gout

Authors:

Erdal Bodakçi

Publisher:

Eskişehir Osmangazi University

Main Topics:

Romatoloji ve Artrit

Journal:

Osmangazi Tıp Dergisi Vol.46 Issue 1, pp.68-74

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001302305

pISSN:

1305-4953

Keywords:

Abstract:

 Patients with gout frequently have multiple comorbidities, including hypertensionHT, cardiovascular disease CVD, renal impairment, diabetes mellitusDM, obesity, hyperlipidemiaHL or metabolic syndrome. These comorbidities and their treatment may have an effect on the choice of therapeutic agent. This study was to identify the comorbidities of gout. The study retrospectively investigated the demographic, clinical, and biochemical variables and comorbid factors of patients diagnosed with gout who applied to the rheumatology department between December 2019 and April 2023. 384 gout patients were included mean age 63.4 years; men 71.6. 299 77.9 of the patients received a diagnosis for the first time. The number of patients with comorbidities was 319 83.0. Hypertension was the most common comorbidity, observed in 255 patients 58.5. Other comorbid diseases were HL in 140 patients 36.4, kidney disease in 132 patients 34.3, coronary artery diseaseCAD in 120 patients 31.2, DM in 100 patients 26.0, heart failure in 65 patients 16.9, osteoporosis in 45 patients 11.7, liver disease in 26 patients 6.7, stroke in 25 patients 6.5, other diseases in 20 patients 5.2, malignancy in 18 patients 4.6 and the number of patients without any comorbidities was 65 16.9. Comorbidities in gout are very common and add further to the diseases morbidity and make its management challenging. Patients with gout should therefore screened for comorbidities and risk factors, which should be addressed as an important part of gout management.

 Patients with gout frequently have multiple comorbidities, including hypertensionHT, cardiovascular disease CVD, renal impairment, diabetes mellitusDM, obesity, hyperlipidemiaHL or metabolic syndrome. These comorbidities and their treatment may have an effect on the choice of therapeutic agent. This study was to identify the comorbidities of gout. The study retrospectively investigated the demographic, clinical, and biochemical variables and comorbid factors of patients diagnosed with gout who applied to the rheumatology department between December 2019 and April 2023. 384 gout patients were included mean age 63.4 years; men 71.6. 299 77.9 of the patients received a diagnosis for the first time. The number of patients with comorbidities was 319 83.0. Hypertension was the most common comorbidity, observed in 255 patients 58.5. Other comorbid diseases were HL in 140 patients 36.4, kidney disease in 132 patients 34.3, coronary artery diseaseCAD in 120 patients 31.2, DM in 100 patients 26.0, heart failure in 65 patients 16.9, osteoporosis in 45 patients 11.7, liver disease in 26 patients 6.7, stroke in 25 patients 6.5, other diseases in 20 patients 5.2, malignancy in 18 patients 4.6 and the number of patients without any comorbidities was 65 16.9. Comorbidities in gout are very common and add further to the diseases morbidity and make its management challenging. Patients with gout should therefore screened for comorbidities and risk factors, which should be addressed as an important part of gout management.

 Patients with gout frequently have multiple comorbidities, including hypertensionHT, cardiovascular disease CVD, renal impairment, diabetes mellitusDM, obesity, hyperlipidemiaHL or metabolic syndrome. These comorbidities and their treatment may have an effect on the choice of therapeutic agent. This study was to identify the comorbidities of gout. The study retrospectively investigated the demographic, clinical, and biochemical variables and comorbid factors of patients diagnosed with gout who applied to the rheumatology department between December 2019 and April 2023. 384 gout patients were included mean age 63.4 years; men 71.6. 299 77.9 of the patients received a diagnosis for the first time. The number of patients with comorbidities was 319 83.0. Hypertension was the most common comorbidity, observed in 255 patients 58.5. Other comorbid diseases were HL in 140 patients 36.4, kidney disease in 132 patients 34.3, coronary artery diseaseCAD in 120 patients 31.2, DM in 100 patients 26.0, heart failure in 65 patients 16.9, osteoporosis in 45 patients 11.7, liver disease in 26 patients 6.7, stroke in 25 patients 6.5, other diseases in 20 patients 5.2, malignancy in 18 patients 4.6 and the number of patients without any comorbidities was 65 16.9. Comorbidities in gout are very common and add further to the diseases morbidity and make its management challenging. Patients with gout should therefore screened for comorbidities and risk factors, which should be addressed as an important part of gout management.

 Gut hastalarında sıklıkla hipertansiyonHT, kardiyovasküler hastalık, böbrek yetmezliği, diyabet mellitusDM, obezite, hiperlipidemiHL veya metabolik sendrom dahil olmak üzere birden fazla komorbidite bulunur. Bu komorbiditeler ve tedavileri gut un seyrini ve tedavi edici ajan seçimini etkileyebilir. Bu çalışma gut a eşlik eden hastalıkları belirlemek amacıyla yapıldı. Çalışmamızda Aralık 2019- Nisan 2023 tarihleri arasında romatoloji polikliniğine başvuran gut tanısı alan hastaların demografik, klinik, biyokimyasal değişkenleri ile komorbid faktörleri geriye dönük araştırıldı. Çalışmaya 384 gut hastası dahil edildi ortalama yaş 63,4 yıl olup erkeklerin oranı 71,6. Hastaların 299 una 77,9 ilk kez tanı konulmuştu. Komorbid hastalığı olan hasta sayısı 319 83,0 idi. Komorbid hastalıklar değerlendirildiğinde en sık görülen hipertansiyondu255 hasta, 58,5. Eşlik eden diğer hastalıklar sırasıyla 140 hastada 36,4 HL, 132 hastada 34,3 böbrek hastalığı, 120 hastada 31,2 koroner arter hastalığı, 100 hastada 26,0 DM, 65 hastada kalp yetmezliği 16,9, 45 hastada 11,7 osteoporoz, 26 hastada 6,7 karaciğer hastalığı, 25 hastada 6,5 inme, 20 hastada 5,2 diğer hastalıklar, 18 hastada 4,6 malignite ve herhangi bir komorbiditesi olmayan hasta sayısı ise 65 16,9 idi. Gutta komorbiditeler çok yaygındır ve hastalığın morbiditesini daha da arttırır ve tedavisini zorlaştırır. Bu nedenle gut hastaları, gut tedavisinin önemli bir parçası olarak ele alınması gereken komorbiditeler ve risk faktörleri açısından taranmalıdır.

Article Details

Comorbidities in Patients with Gout

Authors:

Erdal Bodakçi

Publisher:

Eskişehir Osmangazi University

Main Topics:

Romatoloji ve Artrit

Journal:

Osmangazi Tıp Dergisi Vol.46 Issue 1, pp.68-74

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001302305

pISSN:

1305-4953

Gout

Comorbidity

Uric acidGut

komorbidite

Ürik asid

Issues

Article Details

Comorbidities in Patients with Gout

Authors: Erdal Bodakçi

Publisher: Eskişehir Osmangazi University

Main Topics: Romatoloji ve Artrit

Journal: Osmangazi Tıp Dergisi Vol.46 Issue 1, pp.68-74

Document Type: Article

Publication Date: 1/2024

Document Language: English

Document ID (Org No.): 2001302305

pISSN: 1305-4953

Gout

Comorbidity

Uric acidGut

komorbidite

Ürik asid

Issues

Authors:

Erdal Bodakçi

Publisher:

Eskişehir Osmangazi University

Main Topics:

Romatoloji ve Artrit

Journal:

Osmangazi Tıp Dergisi Vol.46 Issue 1, pp.68-74

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001302305

pISSN:

1305-4953